Microorganism producing o-acetyl-homoserine, and method for producing o-acetyl-homoserine by using same

ABSTRACT

The present disclosure relates to a protein having the activity of exporting O-acetylhomoserine and a novel modified protein thereof, a microorganism capable of producing O-acetylhomoserine with enhanced expression of the protein, and a method for producing O-acetylhomoserine using the microorganism.

TECHNICAL FIELD

The present disclosure relates to a protein having the activity ofexporting O-acetylhomoserine and a novel modified protein thereof, amicroorganism capable of producing O-acetylhomoserine with enhancedexpression of the protein, and a method for producing O-acetylhomoserineusing the microorganism.

BACKGROUND ART

Methionine, which can be produced by chemical and biological synthesis,is used as a raw material for the synthesis of infusions and medicinesas well as for the synthesis of feed and food additives. Recently, atwo-step process for producing L-methionine from an L-methionineprecursor, produced via fermentation, by an enzyme conversion reactionwas disclosed (International Patent Publication No. WO 2008/013432).International Patent Publication No. WO 2008/013432 discloses thatO-succinylhomoserine and O-acetylhomoserine can be used as a methionineprecursor in the two-step process, and it is very important to producemethionine precursors in high yield for economical large-scaleproduction of methionine.

LeuE is known as a leucine export protein. As one of the proteinsbelonging to homoserine/homoserine lactone efflux protein (RhtB) family,LeuE is a protein present in the inner membrane and is known to have therole of exporting leucine and its analogues as a putativeuncharacterized transport protein.

In the prior art relating to LeuE, it is known that a purine nucleosideor purine nucleotide can be produced by enhancing an amino acid sequenceof leuE (yeaS) gene or a modified amino acid sequence thereof, and theamount of amino acid production can be improved. Additionally, amodified leuE having the activity of exporting cysteine is known.

DISCLOSURE Technical Problem

The inventors of the present disclosure have made many efforts toimprove the production of O-acetylhomoserine, and as a result, they havediscovered a protein which has the activity of exportingO-acetylhomoserine and a modified protein thereof, thereby completingthe present disclosure.

Technical Solution

An object of the present disclosure is to provide a polypeptide havingthe activity of exporting O-acetylhomoserine.

Another object of the present disclosure is to provide a polynucleotidewhich encodes the polypeptide.

Still another object of the present disclosure is to provide amicroorganism of the genus Escherichia producing O-acetylhomoserine, inwhich a polypeptide having the activity of exporting O-acetylhomoserineis included or overexpressed.

Still another object of the present disclosure is to provide a methodfor producing O-acetylhomoserine, which includes: culturing amicroorganism of the genus Escherichia producing O-acetylhomoserine in amedium; and recovering O-acetylhomoserine from the culturedmicroorganism or the cultured medium.

Still another object of the present disclosure is to provide a methodfor producing L-methionine, which includes: culturing the microorganismof the genus Escherichia producing O-acetylhomoserine in a medium; andconverting the O-acetylhomoserine to L-methionine by treating thecultured microorganism or the cultured medium or the O-acetylhomoserinerecovered from the cultured microorganism or the cultured medium withmethyl mercaptan and a methionine-converting enzyme.

Advantageous Effects of the Invention

The microorganism of the present disclosure including a modified LeuE orLeuE, which are inner membrane proteins, has enhanced activity ofexporting O-acetylhomoserine, and thus the production efficiency ofO-acetylhomoserine can be enhanced. Accordingly, the microorganism ofthe present disclosure can be used for efficient production ofO-acetylhomoserine. Additionally, O-acetylhomoserine produced with highefficiency may be used for economical large-scale production ofL-methionine.

BEST MODE

To achieve the above objects, an aspect of the present disclosureprovides a polypeptide having the activity of exportingO-acetylhomoserine, in which at least one amino acid selected from thegroup consisting of valine at position 1, leucine at position 30,phenylalanine at position 95, and phenylalanine at position 165 in theamino acid sequence of SEQ ID NO: 1 is substituted with another aminoacid.

As used herein, the term “O-acetylhomoserine”, which is a specificintermediate material in the methionine biosynthesis pathway ofmicroorganisms, refers to an acetyl derivative of L-homoserine.O-acetylhomoserine is known to be produced by reacting homoserine andacetyl-CoA catalyzed by homoserine acetyltransferase, and it has theformula of C₆H₁₁NO₄.

As used herein, the term “peptide having the activity of exportingO-acetylhomoserine” refers to a polypeptide having the function ofexporting O-acetylhomoserine in a cell of a microorganism to the outsideof the cell. Specifically, the peptide may refer to a LeuE proteinhaving the activity of exporting O-acetylhomoserine and a modifiedprotein thereof, but the peptide is not particularly limited thereto aslong as it has the activity of exporting O-acetylhomoserine.

As used herein, with regard to amino acid transporters, the term “LeuE”,which is a protein belonging to the homoserine/homoserine lactone effluxprotein (RhtB) family, refers to a protein present in the innermembrane, but its exact function is not known. In this regard, theinventors of the present disclosure first confirmed that LeuEspecifically exports O-acetylhomoserine.

The LeuE may be a protein derived from a microorganism of the genusEscherichia, and specifically LeuE derived from E. coli, but any LeuEhaving the activity of exporting O-acetylhomoserine can be included tothe scope of the present disclosure without limitation with regard tothe origin of the microorganism.

Specifically, the peptide having the activity of exportingO-acetylhomoserine may be a protein having the amino acid sequence ofSEQ ID NO: 1. Additionally, the peptide may be a protein which has anamino acid sequence having the activity of exporting O-acetylhomoserinesubstantially the same as or equivalent to that of the amino acidsequence of SEQ ID NO: 1, while having a homology of at least 70%,specifically at least 80%, and more specifically at least 90% to theamino acid sequence of SEQ ID NO: 1. Alternatively, the peptide may bean amino acid sequence having such homology where there is deletion,modification, substitution, or addition in part of the amino acidsequence having the activity of exporting O-acetylhomoserinesubstantially the same as or equivalent to that of the amino acidsequence of SEQ ID NO: 1, and it is obvious that this peptide alsobelongs to the scope of the present disclosure.

As used herein, the term “modified polypeptide” of the polypeptidehaving the activity of exporting O-acetylhomoserine refers to apolypeptide that has enhanced activity of exporting O-acetylhomoserinecompared to that of native wild-type polypeptide or unmodifiedpolypeptide. Specifically, the modified polypeptide is a peptide whichhas enhanced activity of exporting O-acetylhomoserine compared to thatof the polypeptide which has the amino acid sequence of SEQ ID NO: 1 dueto a modification of at least one amino acid in the amino acid sequenceof SEQ ID NO: 1.

For example, the modified polypeptide may be a polypeptide in which atleast one amino acid selected from the group consisting of valine atposition 1, leucine at position 30, phenylalanine at position 95, andphenylalanine at position 165 in the amino acid sequence of SEQ ID NO: 1is substituted with another amino acid. Specifically, the modifiedpolypeptide may be a polypeptide in which valine at position 1 in theamino acid sequence of SEQ ID NO: 1 is substituted with methionine;phenylalanine at position 30 in the amino acid sequence of SEQ ID NO: 1is substituted with any one selected from the group consisting ofalanine, tryptophan, leucine, valine, glycine, serine, asparagine,aspartic acid, histidine, isoleucine, proline, tyrosine, glutamine,lysine, glutamic acid, cysteine, threonine, and arginine; leucine atposition 95 in the amino acid sequence of SEQ ID NO: 1 is substitutedwith any one selected from the group consisting of valine,phenylalanine, alanine, glycine, threonine, asparagine, aspartic acid,histidine, isoleucine, serine, proline, tyrosine, glutamine, lysine,glutamic acid, cysteine, tryptophan, and arginine; or phenylalanine atposition 165 in the amino acid sequence of SEQ ID NO: 1 is substitutedwith any one selected from the group consisting of alanine, tryptophan,leucine, valine, glycine, serine, asparagine, aspartic acid, histidine,isoleucine, proline, tyrosine, glutamine, lysine, glutamic acid,cysteine, threonine, and arginine. More specifically, the modifiedpolypeptide may be a polypeptide in which valine at position 1 in theamino acid sequence of SEQ ID NO: 1 is substituted with methionine;phenylalanine at position 30 in the amino acid sequence of SEQ ID NO: 1is substituted with any one selected from the group consisting ofalanine, tryptophan, leucine, valine, glycine, serine, asparagine,aspartic acid, and histidine; leucine at position 95 in the amino acidsequence of SEQ ID NO: 1 is substituted with any one selected from thegroup consisting of valine, phenylalanine, alanine, glycine, threonine,asparagine, aspartic acid, and histidine; or phenylalanine at position165 in the amino acid sequence of SEQ ID NO: 1 is substituted with anyone selected from the group consisting of alanine, tryptophan, leucine,valine, glycine, serine, asparagine, aspartic acid, and histidine. Evenmore specifically, the modified polypeptide may be a polypeptide inwhich valine at position 1 in the amino acid sequence of SEQ ID NO: 1 issubstituted with methionine; and phenylalanine at position 30, leucineat position 95, and phenylalanine at position 165 in the amino acidsequence of SEQ ID NO: 1 is substituted with another amino acid. Evenmore specifically, the modified polypeptide may be a polypeptideconsisting of an amino acid sequence of SEQ ID NO: 2, 133, 134, 137,138, 141, or 142. Specifically, the modified polypeptide may be aprotein which has an amino acid sequence having enhanced activity ofexporting O-acetylhomoserine substantially the same as or equivalent tothat of the amino acid sequence of the modified polypeptide, whilehaving a homology of at least 70%, specifically at least 80%, and morespecifically at least 90% to the above amino acid sequences.Alternatively, in an amino acid sequence having such homology and havingenhanced activity of exporting O-acetylhomoserine substantially the sameas or equivalent to that of the amino acid sequence of the modifiedpolypeptide, the amino acid sequence may be one where there is deletion,modification, substitution, or addition in part of the amino acidsequence. The polypeptide is an example of a modified polypeptide of thepolypeptide with enhanced activity of exporting O-acetylhomoserinecompared to that of the native wild-type polypeptide or unmodifiedpolypeptide, but the polypeptide is not limited thereto. As used herein,the term “natural native state or unmodified state” refers to a statewhere the introduction of the corresponding polypeptide or theintroduction of modification of activity in the present disclosure hasnot been achieved.

As used herein, the term “homology” refers to the degree of identitybetween nucleotides or amino acid residues of two amino acid sequencesor nucleic acid sequences of a protein-encoding gene determined afteraligning them to maximally match with each other for a particularcomparison region. When the homology is sufficiently high, theexpression products of the corresponding gene may have the same orsimilar activity. The percentage of the sequence identity can bedetermined using a known sequence comparison program (e.g., BLAST(NCBI), CLC Main Workbench (CLC bio), MegAlign (DNASTAR Inc), etc.).

An aspect of the present disclosure provides a polynucleotide whichencodes the polypeptide having the activity of exportingO-acetylhomoserine. In the present disclosure, the polypeptide havingthe activity of exporting O-acetylhomoserine is the same as explainedabove.

For example, the polynucleotide may be one in which the initiation codonis substituted with ATG and may be the nucleotide sequence of SEQ ID NO:4, 135, 136, 139, 140, 143, or 144 but the nucleotide sequence is notlimited thereto. Additionally, with regard to the polynucleotide, thenucleotide sequence and modified nucleotide sequences thereof encodingthe same amino acid sequence are also included in the present disclosurebased on codon degeneracy. For example, the nucleotide sequence may bemodified to have an optimum codon depending on the microorganism beingused.

Specifically, the nucleotide sequence may be one which encodes an aminoacid sequence having the activity of exporting O-acetylhomoserinesubstantially the same as or equivalent to that of the above nucleotidesequences, while having a homology of at least 70%, specifically atleast 80%, and more specifically at least 90% to the above amino acidsequences. Alternatively, the nucleotide sequence may be a sequencecapable of hybridizing with a probe, which can be prepared from a knowngene sequence (e.g., a sequence complementary to all or part of theabove nucleotide sequences), under stringent conditions to encode aprotein having the activity of exporting O-acetylhomoserine. As usedherein, the term “stringent condition” refers to a condition in whichso-called a specific hybrid is formed while a non-specific hybrid is notformed. For example, the stringent condition may include a condition inwhich genes having a high homology (e.g., 80% or more, specifically 90%or more, more specifically 95% or more, even more specifically 97% ormore, and even more specifically 99% or more) can hybridize betweenthem, whereas genes having a lower homology thereof cannot hybridizewith each other; or conditions for conventional southern hybridization(i.e., conditions for washing once, and specifically two or three timesunder a salt concentration and temperature corresponding to 60° C.,1×SSC, and 0.1% SDS; specifically under 60° C., 0.1×SSC, and 0.1% SDS,and more specifically under 68° C., 0.1×SSC, and 0.1% SDS) (Sambrook etal., Molecular Cloning: A Laboratory Manual, 3rd Ed., Cold Spring HarborLaboratory Press, Cold Spring Harbor, N.Y. (2001)). The probe used forthe hybridization may optionally be a part of the nucleotide sequencecomplementary to the above nucleotide sequences. Such a probe can beprepared by PCR using an oligonucleotide prepared based on a knownsequence as a primer and a gene fragment containing such a nucleotidesequence as a template. For example, as the probe, a gene fragment ofabout 300 bp may be used. More specifically, when a gene fragment ofabout 300 bp is used as a probe, the conditions of 50° C., 2×SSC, and0.1% SDS are listed as washing conditions for the hybridization.

The genes used in the present disclosure, the protein sequences and thepromoter sequences they encode can be obtained from a known database(e.g., GenBank of NCBI), but are not limited thereto.

An aspect of the present disclosure relates to a microorganism in whichthe polypeptide having the activity of exporting O-acetylhomoserine or amodified polypeptide thereof is included or overexpressed. Specifically,the microorganism may be a microorganism producing O-acetylhomoserine ora modified polypeptide thereof, in which a polypeptide consisting of theamino acid sequence of SEQ ID NO: 1 is included or overexpressed.

The polypeptide having the activity of exporting O-acetylhomoserine andthe modified polypeptide thereof are the same as explained above.

As used herein, the term “microorganism producing O-acetylhomoserine”refers to a microorganism capable of producing O-acetylhomoserine in themicroorganism and exporting it to a medium. The activity of producingO-acetylhomoserine can be provided or enhanced by natural or artificialmutations or species improvement. Specifically, those microorganismswhich produce O-acetylhomoserine can be included regardless of theirmicrobial origin, as long as they can produce O-acetylhomoserine. In anembodiment, the microorganism may be one belonging to the genusEscherichia, and more specifically, Escherichia coli.

Meanwhile, in the present disclosure, the microorganisms producingO-acetylhomoserine may be a modified microorganism in which a knownmodification is additionally introduced with regard to relatedmechanisms such as homoserine biosynthesis-related pathways andmechanisms related to exporting O-acetylhomoserine, etc. so as toenhance the productivity of O-acetylhomoserine apart from the LeuE.

Another specific embodiment of the present disclosure may relate to themicroorganism producing O-acetylhomoserine in which, additionally, theactivity of cystathionine synthase is inactivated. Specifically, themicroorganism may be one in which the gene encoding cystathioninesynthase (metB) is deletion or its expression is weakened compared tothat of an unmodified microorganism, but is not limited thereto. Theamino acid sequence of the metB gene can be obtained from a knowndatabase and any amino acid sequence having the activity ofcystathionine synthase can be included without limitation (e.g., aprotein having the amino acid sequence of SEQ ID NO: 5). The proteinhaving the amino acid sequence of SEQ ID NO: 5 may be a protein encodedby the nucleotide sequence of SEQ ID NO: 6, but is not limited thereto.

Additionally, still another specific embodiment of the presentdisclosure may relate to the microorganism producing O-acetylhomoserinein which, additionally, the activity of homoserine kinase isinactivated. Specifically, the microorganism may be one in which theactivity of homoserine kinase is reduced compared to its endogenousactivity of an unmodified microorganism or is removed. For example, themicroorganism may be one in which the gene (thrB) encoding homoserinekinase is linked to a weaker promoter compared to a native promoter, oris modified or deletion to have weak activity, but the promoter is notlimited thereto. The amino acid sequence of the thrB gene can beobtained from a known database and any amino acid sequence having theactivity of homoserine kinase can be included without limitation (e.g.,a protein having the amino acid sequence of SEQ ID NO: 7). The proteinhaving the amino acid sequence of SEQ ID NO: 7 may be a protein encodedby the nucleotide sequence of SEQ ID NO: 8, but is not limited thereto.

As used herein, the term “inactivation” of the protein refers to a casewhere the activity of the protein of a microorganism is reduced comparedto the enzyme activity possessed by the microorganism in a nativewild-type protein or unmodified protein; a case where the protein is notexpressed at all; or a case where the protein is expressed but exhibitsno activity. The inactivation is a concept including a case where theactivity of the enzyme itself is reduced or removed compared to theactivity of the enzyme originally possessed by the microorganism due tothe modification, etc. of the gene encoding the enzyme; a case where theentire activity level of the enzyme in a cell is reduced or removedcompared to the activity of the enzyme originally possessed by thewild-type strain of the microorganism due to the inhibition of theexpression or translation of the gene encoding the enzyme; a case wherepart or the entirety of the gene is deleted; and a combination thereof;but the inactivation is not limited thereto.

The inactivation of an enzyme may be achieved by applying variousmethods well known in the art. Examples of the methods may include amethod of substituting the gene encoding the enzyme on the chromosomewith a gene modified to reduce the activity of the enzyme, including thecase when the enzyme activity is removed; a method of introducing amodification in the expression control sequence of the gene encoding theenzyme on the chromosome; a method of substituting the expressioncontrol sequence of the gene encoding the enzyme with a sequence havingweak or no activity; a method of deleting part or the entirety of thegene encoding the enzyme on the chromosome; a method of introducing anantisense oligonucleotide (e.g., antisense RNA) which bindscomplementary to a transcript of the gene on the chromosome, therebyinhibiting the translation from the mRNA into the enzyme; a method ofartificially incorporating a sequence complementary to the SD sequenceinto the upstream of the SD sequence of the gene encoding the enzyme,forming a secondary structure, thereby making the attachment of ribosomethereto impossible; a method of incorporating a promoter to the 3′terminus of the open reading frame (ORF) to induce a reversetranscription (reverse transcription engineering (RTE)), etc., and alsoa combination thereof, but the methods are not particularly limitedthereto.

The method of modifying the expression control sequence may be performedby inducing a modification of the expression control sequence bydeletion, insertion, non-conservative or conservative substitution, or acombination thereof in the nucleic acid sequence of the expressioncontrol sequence so as to further weaken the activity of the expressioncontrol sequence; or by substituting with a nucleic acid having weakeractivity. The expression control sequence may include a promoter, anoperator sequence, a sequence encoding a ribosome-binding region, andsequences controlling the termination of transcription and translation,but is not limited thereto.

Furthermore, the gene sequence on the chromosome may be modified byinducing a modification in the sequence by deletion, insertion,non-conservative or conservative substitution, or a combination thereofin the gene sequence for further weakening the enzyme activity; or bysubstituting with a gene sequence which was improved to have weakeractivity or a gene sequence which was improved to have no activity, butthe method is not limited thereto.

Additionally, the method of deleting part or the entirety of a geneencoding an enzyme may be performed by substituting the polynucleotideencoding the endogenous target protein within the chromosome with apolynucleotide or marker gene having a partial deletion in the nucleicacid sequence using a vector for chromosomal insertion within abacterial strain. In an exemplary embodiment of the method of deletingpart or the entirety of a gene, a method for deleting a gene byhomologous recombination may be used, but the method is not limitedthereto.

As used herein, the term “part” may vary depending on the kinds ofpolynucleotides, and it may specifically refer to 1 to 300, morespecifically 1 to 100, and even more specifically 1 to 50, but is notparticularly limited thereto.

As used herein, the term “homologous recombination” refers to geneticrecombination that occurs via crossover at genetic chain loci having amutual homology.

Furthermore, still another specific embodiment of the present disclosuremay relate to the microorganism producing O-acetylhomoserine in which,additionally, the activity of homoserine acetyltransferase is enhancedcompared to that of an unmodified microorganism. Specifically, themicroorganism may be one in which the activity of homoserineacetyltransferase is enhanced compared to that of an unmodifiedmicroorganism, and particularly, may be one in which a modified metAgene encoding homoserine acetyltransferase with enhanced activity isintroduced. The modified metA gene may be a gene encoding one in whichthe 111^(th) amino acid of homoserine acetyltransferase is substitutedwith glutamic acid and the 112^(th) amino acid of homoserineacetyltransferase is substituted with histidine, but is not limitedthereto. The modified metA gene may include without limitation any aminoacid sequence having enhanced activity of homoserine acetyltransferasecompared to that of its wild-type, and for example, may be a proteinhaving the amino acid sequence of SEQ ID NO: 10. Embodiments of thepreparation of the modified metA gene and use thereof, a strain havingenhanced activity of homoserine acetyltransferase, etc. are disclosed inKorean Patent No. 10-1335841, and the entire specification of the patentmay be incorporated herein as a reference for the present disclosure.

Additionally, still another specific embodiment of the presentdisclosure may relate to a microorganism producing O-acetylhomoserinebelonging to the genus Escherichia in which, additionally, the activityof aspartate semialdehyde dehydrogenase, pyridine nucleotidetranshydrogenase, or a combination thereof is enhanced compared to thatof an unmodified microorganism.

Additionally, still another specific embodiment of the presentdisclosure may relate to a microorganism producing O-acetylhomoserine inwhich, additionally, the activity of phosphoenolpyruvate carboxylase,aspartate aminotransferase, or a combination thereof is enhancedcompared to that of an unmodified microorganism. As used herein, theterm “enhancement” refers to enhancing the activity level of a proteinpossessed by a microorganism. Enhancement of the activity of a proteinis not limited as long as it can enhance the activity of each proteincompared to that of the native wild-type protein or unmodified protein,as in the enhancement of the activity of a target protein. Theenhancement may be performed by a method selected from the groupconsisting of i) a method of increasing the copy number of apolynucleotide encoding each protein, ii) a method of introducing amodification in the expression control sequence for increasing theexpression of the polynucleotide, iii) a method of modifying thepolynucleotide sequence on the chromosome for enhancing the activity ofeach protein, and iv) a combination thereof. Specifically, theenhancement may be performed by a method selected from the groupconsisting of a method of inserting a polynucleotide including anucleotide sequence encoding each protein into the chromosome, a methodof introducing the polynucleotide into a microorganism after introducingit into a vector system, a method of introducing a promoter withenhanced activity into an upstream region of the nucleotide sequenceencoding each protein or introducing each protein with a modification onits promoter, a method of modifying the nucleotide sequence in the5′-UTR region, and a method of introducing a modified nucleotidesequence of the nucleotide sequence encoding each protein, but themethods of enhancement are not limited thereto.

Still another aspect of the present disclosure relates to a method forproducing O-acetylhomoserine including culturing the microorganism ofthe genus Escherichia producing O-acetylhomoserine in a medium.

Specifically, the above method relates to a method for producingO-acetylhomoserine including culturing the microorganism of the genusEscherichia producing O-acetylhomoserine in a medium, and recoveringO-acetylhomoserine from the cultured microorganism or the culturedmedium.

As used herein, the term “culture” refers to growing a microorganism inan appropriately-adjusted environment. In the present disclosure, theculture process may be performed using an appropriate medium and cultureconditions well known in the art. The culture process may be easilyadjusted for use by one of ordinary skill in the art according to thestrain being selected. The culture may be performed in a batch process,continuous culture, fetch-batch culture, etc. known in the art, but isnot particularly limited thereto. The medium and other cultureconditions used for culturing the microorganism of the presentdisclosure may not be particularly limited, but any mediumconventionally used for culturing microorganisms of the genusEscherichia may be used. Specifically, the microorganism of the presentdisclosure may be cultured under an aerobic condition in a common mediumcontaining an appropriate carbon, nitrogen, and phosphorus sources,inorganic compounds, amino acids, and/or vitamins, etc., while adjustingtemperature, pH, etc.

In the present disclosure, the carbon sources may include carbohydratessuch as glucose, fructose, sucrose, maltose, mannitol, sorbitol, etc.;alcohols such as sugar alcohol, glycerol, etc.; organic acids such aspyruvic acid, lactic acid, citric acid, etc.; amino acids such asglutamic acid, methionine, lysine, etc., but the carbon sources are notlimited thereto. Additionally, natural organic nutrients such as starchhydrolysate, molasses, blackstrap molasses, rice bran, cassava, sugarcane bagasse, corn steep liquor, etc. may be used. Specifically,carbohydrates such as glucose and sterilized pretreated molasses (i.e.,molasses converted to reducing sugar) may be used, and additionally,various other carbon sources in an appropriate amount may be usedwithout limitation. These carbon sources may be used alone or in acombination of at least two kinds.

Examples of the nitrogen sources may include inorganic nitrogen sources(e.g., ammonia, ammonium sulfate, ammonium chloride, ammonium acetate,ammonium phosphate, ammonium carbonate, ammonium nitrate, etc.); aminoacids (glutamic acid, methionine, glutamine, etc.); and organic nitrogensources (e.g., peptone, N-Z amine, meat extract, yeast extract, maltextract, corn steep liquor, casein hydrolysate, fish or decompositionproduct thereof, defatted soybean cake or decomposition product thereof,etc.). These nitrogen sources may be used alone or in a combination ofat least two kinds, but are not limited thereto.

Examples of the phosphorus sources may include monopotassium phosphate,dipotassium phosphate, and sodium-containing salts correspondingthereto. Examples of inorganic compounds to be used may include sodiumchloride, calcium chloride, iron chloride, magnesium sulfate, ironsulfate, manganese sulfate, calcium carbonate, etc. Additionally, aminoacids, vitamins, and/or appropriate precursors may be included, but arenot limited thereto. These media or precursors may be added in a batchculture process or continuous culture process to a culture, but are notlimited thereto.

During the culture period in the present disclosure, the pH of a culturemay be adjusted by adding a compound such as ammonium hydroxide,potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. tothe culture in an appropriate manner. Additionally, during the cultureperiod, an antifoaming agent, such as fatty acid polyglycol ester, maybe added to prevent foam generation. Additionally, for maintaining theaerobic state of the culture, oxygen or an oxygen-containing gas may beinjected into the culture, while for maintaining the anaerobic andmicroaerobic states of the culture, nitrogen, hydrogen, or carbondioxide gas may be injected without the injection of air.

The culture temperature may normally be from 27° C. to 37° C., andspecifically from 30° C. to 35° C., but the culture temperature is notlimited thereto. Additionally, the culture may be continued until theproduction of desired material(s) can be obtained, and specifically for10 hours to 100 hours, but is not limited thereto.

The recovery of O-acetylhomoserine may be performed using the method ofculturing a microorganism of the present disclosure. For example, thetarget O-acetylhomoserine can be recovered from a culture using anappropriate method known in the art (e.g., a batch-type culture,continuous culture, or fed-batch culture, etc.). For example, methodssuch as centrifugation, filtration, anion exchange chromatography,crystallization, HPLC, etc. may be used, and additionally, a combinedmethod of appropriate methods known in the art may be used.

The recovery process may include a separation process and/or apurification process.

An aspect of the present disclosure relates to a method for producingL-methionine, which includes culturing the microorganism of the genusEscherichia producing O-acetylhomoserine in a medium; and converting theO-acetylhomoserine to L-methionine by treating the culturedmicroorganism or the cultured medium or the O-acetylhomoserine recoveredfrom the cultured microorganism or the cultured medium with methylmercaptan and a methionine-converting enzyme.

For example, methionine can be produced from O-acetylhomoserine, whichis recovered from a culture of a microorganism of the genus Escherichiaproducing O-acetylhomoserine in a medium, by a two-step process (KoreanPatent No. 10-0905381).

The two-step process includes a process of producing L-methionine and anorganic acid by an enzyme reaction using an enzyme having the activityof converting O-acetylhomoserine to methionine using O-acetylhomoserineand methyl mercaptan as substrates or a strain containing the enzyme.

The methionine-converting enzyme includes all of the enzymes thatconvert O-acetylhomoserine to methionine, and particularlyO-acetylhomoserine sulfhydrylase, but is not limited thereto.

Specifically, the O-acetylhomoserine sulfhydrylase to be used may be onederived from microbial strains belonging to the genus Leptospira, thegenus Chromobacterium, and the genus Hyphomonas, and more specifically,one derived from microbial strains belonging to the genus Leptospirameyeri, Pseudomonas aurogenosa, Hyphomonas neptunium, andChromobacterium violaceum.

The above reaction is shown below:

CH₃SH+O-acetyl-L-homoserine<=>acetate+methionine

Such additional process of producing methionine is disclosed in KoreanPatent No. 10-0905381, and the entire specification of the patent may beincluded as a reference for the present disclosure.

DETAILED DESCRIPTION OF THE INVENTION

Hereinafter, the present disclosure will be described in detail throughexemplary embodiments. However, these exemplary embodiments are providedfor the purpose of illustration only and are not intended to limit thescope of the present disclosure.

REFERENCE EXAMPLE 1 Preparation of Strains Producing O-acetylhomoserine

1-1. Deletion of metB Gene in Wild-Type E. coli

To produce strains producing O-acetylhomoserine, E. coli, which is arepresentative microorganism among the microorganisms of the genusEscherichia, was used. For this purpose, E. coli K12 W3110 (ATCC 27325),a wild-type E. coli, was obtained from the American Type CultureCollection (ATCC) and used. A strain which has defects in the metB gene(SEQ ID NO: 6) encoding cystathionine gamma synthase and the thrB gene(SEQ ID NO: 8) encoding homoserine kinase in E. coli K12 W3110 strainwas prepared. The thus-prepared strain producing O-acetylhomoserine wasnamed W3-BT. An embodiment with regard to the deletion of metB and thrBgenes deletion strains is disclosed in Korean Patent No. 10-0905381 orInternational Patent Publication WO 2008/013432 (see particularly,Examples 1-1 and 1-2 of Korean Patent No. 10-0905381), and the entirespecification of the patent may be included herein as a reference forthe present disclosure.

1-2. Preparation of Strain Introduced with Modified Meta Gene HavingActivity of Homoserine Acetyltransferase

To enhance the activity of homoserine acetyltransferase in the strainobtained in Reference Example 1-1, it was attempted to introduce themodified metA gene (SEQ ID NO: 10) encoding homoserine acetyltransferasehaving enhanced activity into the strain. In an attempt to prepare sucha strain, a pCL_Pcj1_metA (EH) plasmid was prepared by the methoddescribed in Examples 1 and 3 of Korean Patent No. 10-1335841.

Then, to prepare a replacement cassette as a way to substitute theabove-prepared modified metA gene by introducing it into the strain, PCRwas performed using the pKD3 vector as a template along with primers ofSEQ ID NO: 23 and SEQ ID NO: 24. Specifically, PCR was repeatedlyperformed for a total of 30 cycles, in which denaturation was performedat 94° C. for 30 seconds, annealing at 55° C. for 30 seconds, andextension at 72° C. for 2 minutes.

For the metA (EH) portion of the replacement cassette, PCR was performedusing pCL-Pcj1-metA (EH) as the template along with primers of SEQ IDNO: 19 and SEQ ID NO: 20, whereas, for the metA wild-type portion,primers of SEQ ID NO: 21 and SEQ ID NO: 22 were used, and thereby therespective PCR products were obtained. Based on 3 PCR products, the metA(EH) replacement cassette containing a chloramphenicol marker wasprepared using the primers of SEQ ID NO: 19 and SEQ ID NO: 22, andintroduced by electroporation into the W3-BT strain, which wastransformed with the pKD46 vector, prepared in Reference Example 1-1.

The strains which were confirmed to have been introduced by the aboveprocess were again transformed with the pCP20 vector and cultured in LBmedium. The strain in which the chloramphenicol marker was removed andthe metA gene was replaced with metA (EH) was named as W3-BTA.

An embodiment with regard to the strain with enhanced activity ofhomoserine acetyltransferase, etc. is disclosed in Korean Patent No.10-1335841 or International Patent Publication WO 2012/087039, and theentire specification of the patent may be included herein as a referencefor the present disclosure.

1-3. Preparation of Strain Including 2 Copies of ppc, aspC, and asdGenes

To increase the productivity of O-acetylhomoserine of the W3-BTA strainprepared in Reference Example 1-2, a known strategy of enhancing thebiosynthetic pathway was introduced. An attempt was made to preparestrains in which the genes, which are associated withphosphoenolpyruvate carboxylase involved in the biosynthesis ofoxaloacetate from phosphoenolpyruvate, aspartate aminotransferaseinvolved in the biosynthesis of aspartate from oxaloacetate, andaspartate-semialdehyde dehydrogenase involved in the biosynthesis ofhomoserine from β-aspartyl phosphate were amplified to 2 copies, thatis, ppc, aspC, and asd genes, were amplified to 2 copies.

For the preparation of the strains, pSG-2ppc, pSG-2aspC, and pSG-2asdplasmids were prepared by the method disclosed in Examples 1-1 to 1-3 ofKorean Patent No. 10-1117012, the above plasmids were introduced intothe W3-BTA strain, and the strain in which the 3 different genes weresequentially amplified to 2 copies was prepared by the method describedin Example 1-5 of the Korean patent. The thus-prepared strain was namedas W3-BTA2PCD (=WCJM).

An embodiment with regard to the strain with enhanced activity ofphosphoenolpyruvate carboxylase, aspartate aminotransferase, andaspartate-semialdehyde dehydrogenase, etc., is disclosed in KoreanPatent No. 10-0905381 or International Patent Publication WO2008/013432, and the entire specification of the patent may be includedherein as a reference for the present disclosure.

1-4. Flask Culture Experiment

To test the amount of O-acetylhomoserine production in the strainsprepared in Reference Examples 1-2 and 1-3, Erlenmeyer flask culture wasperformed. W3110, W3-BTA, and WCJM strains were seeded in LB medium andcultured at 33° C. overnight. Single colonies were seeded in 3 mL of LBmedium and incubated at 33° C. for 5 hours, diluted 200-fold in a 250 mLErlenmeyer flask containing 25 mL of medium for producingO-acetylhomoserine, and incubated again at 33° C. at 200 rpm for 30hours, and the amount of O-acetylhomoserine production was confirmed byHPLC analysis. The composition of the medium used is summarized in Table1 below.

TABLE 1 Composition of flask medium producing O-acetylhomoserineComposition Concentration (per Liter) Glucose 40 g Ammonium Sulfate 17 gKH₂PO₄ 1.0 g MgSO₄•7H₂O 0.5 g FeSO₄•7H₂O 5 mg MnSO₄•8H₂O 5 mg ZnSO₄ 5 mgCalcium Carbonate 30 g Yeast Extract 2 g Methionine 0.15 g Threonine0.15 g

The amount of O-acetylhomoserine production was confirmed by HPLCanalysis after culturing for 30 hours using the above medium, and theresults are summarized in Table 2 below.

TABLE 2 O-Acetylhomoserine production by flask culture Glucose OD (562nm) Consumption (g/L) O-AH (g/L) W3110 14.2 40 0 W3-BTA 8.4 36 0.9 WCJM9.6 35 1.2

As can be seen in Table 2 above, O-acetylhomoserine was not produced atall in the wild-type strain W3110, however, the W3-BTA strain producedO-acetylhomoserine (O-AH) at a concentration of 0.9 g/L in, and the WCJMstrain with an enhanced biosynthetic pathway produced O-acetylhomoserine(O-AH) at a concentration of 1.2 g/L.

EXAMPLE 1 Selection of Membrane Proteins Increasing O-acetylhomoserineProductivity

The inventors of the present disclosure made an attempt to apply LeuE(SEQ ID NO: 1) derived from Escherichia coli, which was disclosed as amembrane protein but has not been disclosed with regard to the activityof exporting O-acetylhomoserine and producing O-acetylhomoserine, toO-acetylhomoserine production.

In order to enhance the leuE gene in the strain, the leuE gene wascloned using a SmaI restriction site of the pCL vector.

First, to prepare the leuE gene, PCR was performed for a total of 30cycles using primers of SEQ ID NOS: 11 and 12, in which denaturation wasperformed at 94° C. for 30 seconds, annealing at 55° C. for 30 seconds,and extension at 68° C. for 1 minute. The resulting PCR product waselectrophoresed on a 1.0% agarose gel and DNA was purified from the 800bp band. The purified DNA was treated with restriction enzyme Smal at37° C. overnight, and after additional purification, leuE gene and thepCL vector were cloned using T4 ligase. After transforming E. coli DH5using the cloned plasmid, the transformed E. coli DH5 were selected onLB plate medium containing spectinomycin (50 μg/mL) to obtain theplasmid. The thus-prepared plasmid was introduced into W3-BTA and WCJMstrains, which are strains producing O-acetylhomoserine. They were namedas W3-BTA/pCL-leuE and WCJM/pCL-leuE, respectively, and flask evaluationon their productivity of O-acetylhomoserine was performed.

Additionally, as the control groups, the empty vector pCL1920 wasintroduced into W3-BTA and WCJM strains in the same method as describedabove, and named as W3-BTA/pCL 1920 and WCJM pCL1920, respectively, andflask evaluation on their productivity of O-acetylhomoserine wasperformed.

Specifically, each strain was plated on LB solid medium and culturedovernight in a 33° C. incubator. A single colony of the strain culturedovernight in LB plate medium was seeded in 3 mL of LB medium andincubated at 33° C. for 5 hours, diluted 200-fold in a 250 mL Erlenmeyerflask containing 25 mL of medium for producing O-acetylhomoserine, andincubated again at 33° C. at 200 rpm for 30 hours, and the amount ofO-acetylhomoserine production was confirmed by HPLC analysis. Theresults are summarized in Table 3 below.

TABLE 3 Measurement of O-acetylhomoserine production by flask cultureGlucose OD (562 nm) Consumption (g/L) O-AH (g/L) W3-BTA/pCL1920 9.5 350.9 W3-BTA/pCL-leuE 8.2 36 1.0 WCJM/pCL1920 9.6 35 1.2 WCJM/pCL-leuE 8.436 1.5

As can be seen in Table 3 above, the WCJM strain introduced with leuEplasmid showed a lower OD compared to that of the control strainintroduced with the empty vector, and the WCJM strain also showed higherglucose consumption. However, the WCJM strain producedO-acetylhomoserine at a concentration of 1.5 g/L, and this could notconfirm that the increase of O-acetylhomoserine production was due tothe introduction of the wild-type leuE. Nevertheless, the results ofbeing capable of controlling OD and increase of glucose consumption rateconfirmed the potential exporting activity of the strain. Accordingly,an attempt was made to select modified strains having enhanced activityof exporting O-acetylhomoserine compared to that of the wild-type strainthrough structural modeling.

EXAMPLE 2 Preparation of Plasmid with Modification of Start Codon ofleuE and Evaluation of O-acetyl Homoserine Productivity

The start codon of wild-type leuE is known to be gtg, which encodesvaline, an amino acid. To confirm the enhanced effect of leuE protein bychanging the start codon to atg (i.e., a methionine-encoding codon), anexperiment to change the start codon based on the plasmid prepared inExample 1 was performed. Specifically, the first amino acid in the aminoacid sequence of SEQ ID NO: 1 was substituted with methionine to enhancethe activity of exporting O-acetylhomoserine. More specifically, aleuE(ATG) modification was prepared. To prepare the leuE(ATG)modification, primers of SEQ ID NO: 145 and SEQ ID NO: 146 were used,and a modified leuE(ATG) gene was prepared by site-specific mutagenesis(site-directed mutagenesis kit, Stratagene, USA). The existing wild-typeplasmid was named as WT, and the initiation codon variant plasmid wasnamed WT_ATG, and the thus-prepared plasmid was introduced to the WCJMstrain and the flask evaluation on its productivity ofO-acetylhomoserine was performed.

Specifically, each strain was plated on LB solid medium and culturedovernight in a 33° C. incubator. The strain cultured overnight in LBplate medium was seeded in 25 mL titer medium and incubated at 33° C. at200 rpm for 40 hours. The results are summarized in Table 4 below.

TABLE 4 Measurement of O-acetylhomoserine production by flask cultureGlucose OD (562 nm) Consumption (g/L) O-AH (g/L) WCJM/pCL-leuE 8.4 361.5 WT WCJM/pCL-leuE 7.6 39 2.6 WT(ATG)

As can be seen in Table 4 above, the strain introduced with the pCL-leuEWT(ATG) plasmid having the start-codon modification showed a lower ODcompared to that of the wild-type strain but showed more rapid glucoseconsumption. The strain introduced with the pCL-leuE WT(ATG) plasmidhaving the start-codon modification produced O-acetylhomoserine at aconcentration of 2.6 g/L, which is an increase of productivity as muchas 173% compared to that of the wild-type strain.

EXAMPLE 3 Preparation of leuE-Modified Plasmid and Evaluation ofProductivity of O-acetylhomoserine

3-1. Preparation of leuE-Modified Plasmid

Experiments to prepare each of the three modified polypeptides whichwere expected to have a stronger exporting activity compared to that ofthe wild-type leuE based on the two kinds of plasmids, i.e.,plasmidpCL-leuE WT and pCL-leuE WT(ATG) prepared in Examples 1 and 2,were performed. Specifically, the positions of leuE modification wereselected via structure modeling to enhance the activity of exportingO-acetylhomoserine, and the amino acids at positions 30, 95, and 165 inthe amino acid sequences of SEQ ID NOS: 1 and 2 were substituted withdifferent amino acids, respectively.

More specifically, L95V, F30A, and F165A modifications were prepared.For the preparation of L95V modification, primers of SEQ ID NOS: 13 and14 were used; for F30A modification, primers of SEQ ID NOS: 25 and 26were used; and for F165A modification, primers of SEQ ID NOS: 27 and 28were used. Modified leuE genes were prepared using site-directedmutagenesis kit (Stratagene, USA) along with each of the primer setsdescribed above. Based on the existing wild-type plasmid WT, themodified plasmid L95V was named as WT_M3; the modified plasmid F30A asWT_M4, and the modified plasmid F165A as WT_M6, respectively.Additionally, based on the plasmid with a start codon modification(i.e., WT(ATG)), the modified plasmid L95V was named as WT(ATG)_M3, themodified plasmid F30A as WT(ATG)_M4, and the modified plasmid F165A asWT(ATG)_M6, respectively. The thus-prepared modified plasmids wereintroduced into the WCJM strain to evaluate the productivity ofO-acetylhomoserine in a flask.

Specifically, each strain was plated on LB plate medium and cultured ina 33° C. incubator overnight. The strain cultured overnight in LB solidmedium was inoculated into a 25 mL of the titer medium, and thencultured in an incubator at 33° C. incubator at 200 rpm for 40 hours.The results are shown in Table 5 below.

TABLE 5 Measurement of O-acetylhomoserine production by flask cultureGlucose OD (562 nm) Consumption (g/L) O-AH (g/L) WCJM/pCL1920 9.6 35 1.3WCJM/pCL-leuE 8.4 36 1.5 WT WCJM/pCL-leuE 8.2 38 2.3 WT_M3 WCJM/pCL-leuE7.9 38 3.7 WT_M4 WCJM/pCL-leuE 8.0 39 4.8 WT_M6 WCJM/pCL-leuE 7.6 39 2.6WT(ATG) WCJM/pCL-leuE 7.5 40 3.1 WT(ATG)_M3 WCJM/pCL-leuE 7.3 39 3.6WT(ATG)_M4 WCJM/pCL-leuE 7.5 40 4.9 WT(ATG)_M6

As can be seen in Table 5 above, all of the 3 strains introduced withthe leuE-modified plasmid showed a decrease in OD compared to that ofthe wild-type, but all of the 3 strains showed more rapid glucoseconsumption compared to that of the wild-type strain, and in particular,the WT(ATG)_M6 strain was shown to produce O-acetylhomoserine at aconcentration of 4.9 g/L, thus showing the highest productivity ofO-acetylhomoserine. Accordingly, it was confirmed that all of the 3modified strains of the present disclosure exhibited enhancedproductivity of O-acetylhomoserine. Additionally, it was confirmed thatwhen the amount of protein expression was increased by modifying thestart codon of leuE, the productivity of O-acetylhomoserine was furtherenhanced.

3-2. Preparation of Biosynthesis Pathway Genes and Modified Plasmids

To maximize the productivity of O-acetylhomoserine, a plasmid capable ofenhancing the biosynthetic pathway to homoserine was prepared. For thecloning of aspartate semialdehyde dehydrogenase, pyridine nucleotidetranshydrogenase, and wild-type LeuE and modified LeuE into the pCLvector, asd and pntAB genes were first introduced into the pCL vector.

First, in obtaining the asd and pntAB genes, the PCR was performed for atotal of 30 cycles, in which denaturation was performed at 94° C. for 30seconds, annealing at 55° C. for 30 seconds, and extension at 68° C. for3 minutes, using primers of SEQ ID NOS: 15 and 16 for asd gene andprimers of SEQ ID NOS: 17 and 18 for pntAB gene. The resulting PCRproducts were electrophoresed on a 1.0% agarose gel and the DNAsrespectively obtained from 1.4 kb (asd) and 3 kb (pntAB) sized bandswere purified.

The purified two genes were ligated using the sewing PCR (a technique inwhich the overlapping parts of two genes are ligated first without usingany primer and then amplified using the primers at both ends). Theconditions for the sewing PCR were performing the PCR described abovefor 10 cycles and then performing PCR for 20 cycles after adding primersof SEQ ID NOS: 15 and 18. As a result, combined fragments of asd-pntABgenes were prepared, and purified by electrophoresis. The purifiedfragments and the pCL vector were treated with Smal at 37° C. overnight,purified further, and the pCL-asd-pntAB plasmid was prepared using T4ligase.

The leuE gene was cloned into the thus-prepared plasmid. In cloning,specifically, to obtain the leuE gene, PCR was performed for a total of30 cycles, in which denaturation was performed at 94° C. for 30 seconds,annealing at 55° C. for 30 seconds, and extension at 68° C. for 1minute, using primers of SEQ ID NOS: 29 and 30.

The resulting PCR product was electrophoresed on a 1.0% agarose gel andthe DNA obtained from 800 bp was purified. The purified DNA and the pCLvector were treated with KpnI at 37° C. overnight, purified further, andthe leuE gene and pCL-asd-pntAB vector were cloned. The cloned plasmidswere transformed into E. coli DH5α, and the transformed E. coli DH5α wasselected in LB plate medium containing spectinomycin (50 μg/mL) and theplasmids were obtained therefrom. The thus-prepared plasmids wereintroduced into the WCJM strain, which is a strain producingO-acetylhomoserine, and a flask evaluation was performed with regard toits productivity of O-acetylhomoserine. The thus-prepared plasmids werea total of 4 kinds and the wild-type and 3 modified strains prepared inExample 2-1 were used. The 4 kinds of plasmids were introduced into theWCJM strain by electroporation and a flask evaluation was performed inthe same manner as in Example 3-1. The results are shown in Table 6-1below.

TABLE 6 Measurement of O-acetylhomoserine production by flask cultureGlucose OD Consumption (562 nm) (g/L) O-AH (g/L) WCJM/pCL-asd-pntAB 9.836 1.8 WCJM/pCL-asd-pntAB-leuE 9.5 37 2.0 WT WCJM/pCL-asd-pntAB-leuE 8.238 3.0 WT_M3 WCJM/pCL-asd-pntAB-leuE 7.5 38 4.2 WT_M4WCJM/pCL-asd-pntAB-leuE 7.8 38 5.9 WT_M6

As can be seen in Table 6 above, as a result of simultaneously enhancingthe biosynthesis pathway and the leuE modification, the productivity ofO-acetylhomoserine was further improved. In particular, in the case ofthe strain in which the pCL-asd-pntAB-leuE WT_M6 plasmid was introduced,the OD was decreased compared to that of the wild-type strain, but thestrain showed more rapid glucose consumption and producedO-acetylhomoserine at a concentration of 5.9 g/L, the highest among thestrains.

EXAMPLE 4 Preparation of leuE Modification by Saturated Mutagenesis andEvaluation of Productivity of O-acetylhomoserine

4-1. Preparation of Strains with leuE Modification by SaturatedMutagenesis and Evaluation Thereof

Modifications were prepared by saturated mutagenesis to producedifferent types of amino acid substitutions of the 3 leuE variants,which had shown high productivity of O-acetylhomoserine. The substitutedamino acids were prepared using 17 kinds of M3 mutation, M4 mutation,and M6 mutation, respectively, using the plasmids prepared in Example 2as the templates. The details are shown in Table 7 below.

TABLE 7 Modified Plasmid Amino Acid Substituted SEQ ID NO of Primers M3L95F SEQ ID NOS: 31, 32 L95A SEQ ID NOS: 33, 34 L95G SEQ ID NOS: 35, 36L95T SEQ ID NOS: 37, 38 L95N SEQ ID NOS: 39, 40 L95D SEQ ID NOS: 41, 42L95H SEQ ID NOS: 43, 44 L95I SEQ ID NOS: 45, 46 L95S SEQ ID NOS: 47, 48L95P SEQ ID NOS: 49, 50 L95Y SEQ ID NOS: 51, 52 L95Q SEQ ID NOS: 53, 54L95K SEQ ID NOS: 55, 56 L95E SEQ ID NOS: 57, 58 L95C SEQ ID NOS: 59, 60L95W SEQ ID NOS: 61, 62 L95R SEQ ID NOS: 63, 64 M4 F30W SEQ ID NOS: 65,66 F30L SEQ ID NOS: 67, 68 F30V SEQ ID NOS: 69, 70 F30G SEQ ID NOS: 71,72 F30S SEQ ID NOS: 73, 74 F30N SEQ ID NOS: 75, 76 F30D SEQ ID NOS: 77,78 F30H SEQ ID NOS: 79, 80 F30I SEQ ID NOS: 81, 82 F30P SEQ ID NOS: 83,84 F30Y SEQ ID NOS: 85, 86 F30Q SEQ ID NOS: 87, 88 F30K SEQ ID NOS: 89,90 F30E SEQ ID NOS: 91, 92 F30C SEQ ID NOS: 93, 94 F30T SEQ ID NOS: 95,96 F30R SEQ ID NOS: 97, 98 M6 F165W SEQ ID NOS: 99, 100 F165L SEQ IDNOS: 101, 102 F165V SEQ ID NOS: 103, 104 F165G SEQ ID NOS: 105, 106F165S SEQ ID NOS: 107, 108 F165N SEQ ID NOS: 109, 110 F165D SEQ ID NOS:111, 112 F165H SEQ ID NOS: 113, 114 F165I SEQ ID NOS: 115, 116 F165P SEQID NOS: 117, 118 F165Y SEQ ID NOS: 119, 120 F165Q SEQ ID NOS: 121, 122F165K SEQ ID NOS: 123, 124 F165E SEQ ID NOS: 125, 126 F165C SEQ ID NOS:127, 128 F165T SEQ ID NOS: 129, 130 F165R SEQ ID NOS: 131, 132

Specifically, leuE-modified genes were prepared by performing asite-directed mutagenesis kit (Stratagene, USA) using the primers shownin Table 7 above. The plasmid was introduced into the WCJM strain andthe flask was evaluated in the same manner as Example 3-1. The resultsare shown in Table 8 below.

TABLE 8 Measurement of O-acetylhomoserine production by flask cultureGlucose Location of Consumption Strain Plasmid Modification OD (562 nm)(g/L) O-AH (g/L) WCJM pCL1920 9.6 35 1.3 pCL-leuE WT 8.4 36 1.5 pCL-leuEWT_M3 L95V 8.2 38 2.3 pCL-leuE WT_M4 F30A 7.9 38 3.7 pCL-leuE WT_M6F165A 8.0 39 4.8 M3 Modification L95F 8.6 38 2.3 L95A 8.3 38 2.2 L95G9.2 37 2.1 L95T 9.4 37.5 2.3 L95N 8.8 38 2.4 L95D 8.7 36 2.2 L95H 9.5 352.3 L95I 9.5 37.5 2.2 L95S 9.3 37 2.5 L95P 9.2 36 2.5 L95Y 8.9 35 2.2L95Q 9.4 38 3.1 L95K 9.2 38.5 2.2 L95E 8.6 37 2.6 L95C 8.9 37.5 2.4 L95W9.9 38 2.1 L95R 9.3 38 2.3 M4 Modification F30W 7.5 38 3.2 F30L 7.2 363.1 F30V 7.3 35 2.6 F30G 8.3 36 3.4 F30S 7.9 35 3.6 F30N 8.2 37 3.5 F30D8.6 38 3.0 F30H 8.8 34 2.9 F30I 8.3 35 3.5 F30P 8.6 35.5 3.1 F30Y 7.9 342.9 F30Q 8.6 34 2.8 F30K 8.8 35 3.1 F30E 7.6 35.5 2.5 F30C 7.9 35 2.4F30T 8.9 36 3.0 F30R 8.6 38.5 2.9 M6 Modification F165W 8.2 39 4.2 F165L8.3 38 4.5 F165V 8.4 38 4.1 F165G 8.0 39 4.6 F165S 7.9 37 4.7 F165N 8.839 4.7 F165D 7.8 38 4.5 F165H 7.9 38 4.5 F165I 7.8 37 4.1 F165P 7.7 37.54.2 F165Y 8.2 38 4.6 F165Q 8.4 38 3.9 F165K 7.6 39 4.0 F165E 7.7 36.54.2 F165C 7.6 36.5 4.3 F165T 8.5 34 3.7 F165R 8.3 38 3.9

As can be seen in Table 8 above, as a result of evaluating each of themodified strains, there was a slight difference in OD and glucoseconsumption rate. However, all of the above modified strains were foundto have an enhanced amount of O-acetylhomoserine production compared tothe WCJM/pCL1920 and WCJM/pCL-leuE WT strains used as the control group.

4-2. Preparation of Strain with Enhanced leuE-Modification in Strainwith High-Yield of O-acetylhomoserine and Evaluation of its Productivityof O-acetylhomoserine

A method for producing a strain capable of producing O-acetylhomoserineby using a strain capable of producing threonine via NTG mutationderived from wild-type W3110 is disclosed (International PatentPublication No. WO 2012/087039). In particular, the thus-prepared strainproducing O-acetylhomoserine with high yield was deposited with theKorean Microorganism Conservation Center under the Accession No.KCCM11146P.

An attempt was made whether the productivity of O-acetylhomoserine canbe further enhanced by introducing the leuE gene and modified strainsthereof based on the above strain.

Specifically, the leuE gene and 3 modified strains thereof wereintroduced by electroporation. The strains introduced were named asKCCM11146P/pCL1920, KCCM11146P/pCL-leuE WT, KCCM11146P/pCL-leuE M3,KCCM11146P/pCL-leuE M4, and KCCM11146P/pCL-leuE M6, respectively. Tomeasure the productivity of O-acetylhomoserine of the leuE gene and 3modified strains thereof, flask culture evaluation was performed.Specifically, LB medium was inoculated with 4 kinds of the above strainsand incubated overnight at 33° C. Then, single colonies were inoculatedinto 3 mL of LB medium and cultured again at 33° C. for 5 hours, diluted200-fold in a 250 mL Erlenmeyer flask containing 25 mL of medium forproducing O-acetylhomoserine, and incubated again at 33° C. at 200 rpmfor 30 hours, and the amount of O-acetylhomoserine production wasconfirmed by HPLC analysis. The results of the experiment are summarizedin Table 9 below.

TABLE 9 Measurement of O-acetylhomoserine production by flask culture ODGlucose (562 nm) Consumption (g/L) O-AH (g/L) KCCM11146P/pCL1920 18.3 4014.2 KCCM11146P/pCL-leuE 17.9 40 16.3 WT KCCM11146P/pCL-leuE 17.5 4016.9 M3 KCCM11146P/pCL-leuE 16.8 40 19.2 M4 KCCM11146P/pCL-leuE 17.2 4018.8 M6

As can be seen in Table 9 above, it was confirmed that the strain whichwas prepared by introducing only the pCL1920 into the KCCM11146P strainproduced 14.2 g/L of O-acetylhomoserine, and the leuE WT strain alsoshowed an increase in the amount of O-acetylhomoserine productioncompared to the original strain. Additionally, all of the 3 modifiedstrains showed a decrease of OD, whereas the M4 strain showed thehighest yield of O-acetylhomoserine production (19.2 g/L). The M4 and M6strains showed an increase in the amount of the O-acetylhomoserineproduction.

The inventors of the present disclosure confirmed that theO-acetylhomoserine production was increased in “KCCM11146P/pCL-leuE M3,M4, and M6 strains”, which are 3 leuE-modified strains of M3, M4, and M6based on the KCCM11146P strain. As a result, they named the strains as“CA05-4009”, “CA05-4010”, and “CA05-4011”, and were deposited with theKCCM on Dec. 15, 2014, under the Accession Nos. KCCM11645P, KCCM11646P,and KCCM11647P, respectively.

EXAMPLE 5 Production of L-methionine Using O-acetylhomoserine CultureSolution Produced and Transferase

An experiment for producing L-methionine by using the culture solutionof O-acetylhomoserine obtained in Example 4 and O-acetylhomoserinesulfhydrylase, which is an enzyme converting O-acetylhomoserine tomethionine, was performed.

O-Acetylhomoserine sulfhydrylase, a converting enzyme, was prepared bythe method provided in Example 1-2 of Korean Patent No. 10-1250651, andthe amount of L-methionine produced by a conversion reaction using themethod provided in Example 3 of Korean Patent No. 10-1250651 wasmeasured. For the O-acetylhomoserine used as the substrate, the culturesolution of KCCM11146P-pCL-leuE M4 (O-AH concentration; 19.2 g/L)obtained in Example 4 in the present disclosure was used, and theconcentration of the L-methionine produced therefrom is shown in Table10 below.

TABLE 10 Time (min) 2 4 6 8 10 MetZ-rsp Methionine 3.21 4.34 4.52 4.785.04 (g/L) Conversion (%) 50% 68% 71% 75% 79%

As can be seen in Table 10 above, it was confirmed that theO-acetylhomoserine contained in the culture solution of theKCCM11146P-pCL-leuE M4 strain obtained in Example 4 was converted tomethionine at a conversion rate of 79% for 10 minutes. From this result,it was confirmed that methionine can be successfully produced using thestrain of the present disclosure.

From the foregoing, a skilled person in the art to which the presentdisclosure pertains will be able to understand that the presentdisclosure may be embodied in other specific forms without modifying thetechnical concepts or essential characteristics of the presentdisclosure. In this regard, the exemplary embodiments disclosed hereinare only for illustrative purposes and should not be construed aslimiting the scope of the present disclosure. On the contrary, thepresent disclosure is intended to cover not only the exemplaryembodiments but also various alternatives, modifications, equivalents,and other embodiments that may be included within the spirit and scopeof the present disclosure as defined by the appended claims.

1. A polypeptide having the activity of exporting O-acetylhomoserine,wherein at least one amino acid selected from the group consisting ofvaline at position 1, phenylalanine at position 30, leucine at position95, and phenylalanine at position 165 in the amino acid sequence of SEQID NO: 1 is substituted with another amino acid.
 2. The polypeptideaccording to claim 1, wherein valine at position 1 in the amino acidsequence of SEQ ID NO: 1 is substituted with methionine; phenylalanineat position 30 in the amino acid sequence of SEQ ID NO: 1 is substitutedwith any one selected from the group consisting of alanine, tryptophan,leucine, valine, glycine, serine, asparagine, aspartic acid, andhistidine; leucine at position 95 in the amino acid sequence of SEQ IDNO: 1 is substituted with any one selected from the group consisting ofvaline, phenylalanine, alanine, glycine, threonine, asparagine, asparticacid, and histidine; or phenylalanine at position 165 in the amino acidsequence of SEQ ID NO: 1 is substituted with any one selected from thegroup consisting of alanine, tryptophan, leucine, valine, glycine,serine, asparagine, aspartic acid, and histidine.
 3. The polypeptideaccording to claim 1, wherein valine at position 1 in the amino acidsequence of SEQ ID NO: 1 is substituted with methionine; andphenylalanine at position 30, leucine at position 95, or phenylalanineat position 165 in the amino acid sequence of SEQ ID NO: 1 issubstituted with another amino acid.
 4. The polypeptide according toclaim 1, wherein the polypeptide is selected from the group consistingof amino acid sequences of SEQ ID NOS: 2, 133, 134, 137, 138, 141, and142.
 5. A polynucleotide encoding the polypeptide having the activity ofexporting O-acetylhomoserine of claim
 1. 6. The polynucleotide accordingto claim 5, wherein the start codon of the polynucleotide isadditionally substituted with ATG.
 7. The polynucleotide according toclaim 5, wherein the polynucleotide is selected from the groupconsisting of nucleic acid sequences of SEQ ID NOS: 4, 135, 136, 139,140, 143, and
 144. 8. A microorganism of the genus Escherichia producingO-acetylhomoserine, wherein a polypeptide consisting of the amino acidsequence of SEQ ID NO: 1 or a modified polypeptide thereof is comprisedor overexpressed.
 9. The microorganism according to claim 8, wherein,with regard to the modified polypeptide, at least one amino acidselected from the group consisting of valine at position 1,phenylalanine at position 30, leucine at position 95, and phenylalanineat position 165 in the amino acid sequence of SEQ ID NO: 1 issubstituted with another amino acid.
 10. The microorganism according toclaim 8, wherein, with regard to the modified polypeptide, valine atposition 1 in the amino acid sequence of SEQ ID NO: 1 is substitutedwith methionine; phenylalanine at position 30 in the amino acid sequenceof SEQ ID NO: 1 is substituted with any one selected from the groupconsisting of alanine, tryptophan, leucine, valine, glycine, serine,asparagine, aspartic acid, and histidine; leucine at position 95 in theamino acid sequence of SEQ ID NO: 1 is substituted with any one selectedfrom the group consisting of valine, phenylalanine, alanine, glycine,threonine, asparagine, aspartic acid, and histidine; or phenylalanine atposition 165 in the amino acid sequence of SEQ ID NO: 1 is substitutedwith any one selected from the group consisting of alanine, tryptophan,leucine, valine, glycine, serine, asparagine, aspartic acid, andhistidine.
 11. The microorganism according to claim 8, wherein, withregard to the modified polypeptide, valine at position 1 in the aminoacid sequence of SEQ ID NO: 1 is substituted with methionine; andphenylalanine at position 30, leucine at position 95, or phenylalanineat position 165 in the amino acid sequence of SEQ ID NO: 1 issubstituted with another amino acid.
 12. The microorganism according toclaim 8, wherein the microorganism of the genus Escherichia isEscherichia coli.
 13. The microorganism according to claim 8, wherein,additionally, the activity of cystathionine synthase is inactivated. 14.The microorganism according to claim 8, wherein, additionally, theactivity of homoserine kinase is inactivated.
 15. The microorganismaccording to claim 8, wherein, additionally, the activity of homoserineacetyltransferase is enhanced compared to that of an unmodifiedmicroorganism.
 16. The microorganism according to claim 8, wherein,additionally, the activities of aspartate semialdehyde dehydrogenase,pyridine nucleotide transhydrogenase, or a combination thereof isenhanced compared to that of an unmodified microorganism.
 17. A methodfor producing O-acetylhomoserine, comprising: culturing themicroorganism of the genus Escherichia producing O-acetylhomoserine ofclaim 8 in a medium; and recovering O-acetylhomoserine from the culturedmicroorganism or the cultured medium.
 18. A method for producingL-methionine, comprising: culturing the microorganism of the genusEscherichia producing O-acetylhomoserine of claim 8 in a medium; andconverting the O-acetylhomoserine to L-methionine by treating thecultured microorganism or the cultured medium or the O-acetylhomoserinerecovered from the cultured microorganism or the cultured medium withmethyl mercaptan and a methionine-converting enzyme.
 19. The methodaccording to claim 18, wherein the methionine-converting enzyme isO-acetylhomoserine sulfhydrylase.